
SMMT Technical Analysis Summary (NASDAQ)
Analyze SMMT on the NASDAQ with RSI, MACD, ADX, Bollinger Bands, support, resistance, momentum, and the latest technical trading signals.
Disclaimer for Technical Analysis Page
The technical indicators and trading signals shown on this page are for informational purposes only and do not constitute financial advice. Stock market investments involve risk, and past performance is not a guarantee of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.Read our Full DisclaimerSMMT Technical Analysis Summary (NASDAQ)
Summit Therapeutics Inc. (NASDAQ: SMMT) stock currently shows a bullish trend on the NASDAQ, supported by momentum and strong buying pressure.
Technical conditions suggest Summit Therapeutics Inc. on the NASDAQ is awaiting a decisive move. This mix signals that Summit Therapeutics Inc. is trading in a balanced range with no clear breakout yet.
RSI (14): 52.44
Stochastic %K: 13.68
Williams %R: -69.02
Rate of Change (ROC): -6.58
Takeaway:Summit Therapeutics Inc. shows neutral momentum, with indicators pointing to indecision.
MACD: 0.37
ADX: 23.43
ATR (14): 1.14
CCI (14): 9.67
Takeaway:Summit Therapeutics Inc. shows a firm trend supported by momentum, though one signal suggests caution.
Takeaway:Summit Therapeutics Inc. trades closer to resistance, supported by stronger momentum within bands.
Takeaway:Summit Therapeutics Inc. trades above the trend line, showing healthy momentum within the channel.
Overall Takeaway:SMMT shows balanced money flow with a slight bearish tilt.
Bullish Signals
RSI above 50 → positive momentum from buyers.
MACD above 0 → bullish trend confirmation.
ADX above 20 → strong underlying trend.
Price trading above middle Bollinger Band → mid-term support intact.
MFI below 80 → room for more buying without overbought risk.
Bearish Signals
MACD below signal line → short-term caution on momentum.
RVI below 50 → vigor tilted toward sellers.
Overall Recommendation:Technical indicators for Summit Therapeutics Inc. are mixed, suggesting a Hold or wait-and-see approach.